PMID- 31564893
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220410
IS  - 1178-6930 (Print)
IS  - 1178-6930 (Electronic)
IS  - 1178-6930 (Linking)
VI  - 12
DP  - 2019
TI  - Intersectin 1 (ITSN1) identified by comprehensive bioinformatic analysis and 
      experimental validation as a key candidate biological target in breast cancer.
PG  - 7079-7093
LID - 10.2147/OTT.S216286 [doi]
AB  - BACKGROUND: As one of the most common cancers, breast carcinoma is the most 
      common disease in women. Intersectin 1 (ITSN1) contributes to the actin 
      cytoskeleton reconstruction in breast cancer. PURPOSE: The objective of this 
      study to explore the functions of ITSN1 in breast carcinoma. METHODS: We 
      downloaded microarray datasets GSE8087, GSE50697, and GSE98238 from the Gene 
      Expression Omnibus database. Differentially expressed genes (DEGs) were used to 
      construct a protein-protein interaction (PPI) network using STRING database, and 
      the modules from PPI network were verified by Cytoscape software. Gene ontology 
      terms and Kyoto Encyclopedia of Gene and Genome pathway were used to analyze the 
      biological functions using the DAVID database. ONCOMINE, GEPIA, UALCAN, and Human 
      Protein Atlas databases were used to investigate the characteristics of ITSN1 for 
      the prognosis of breast carcinoma. Cell counting kit-8, flow cytometry, and 
      colony formation assays were used to detect cell viability, cell apoptosis, and 
      cell proliferation. RT-PCR and Western blot assays were used to detect ITSN1, 
      Ki67, and cleaved caspase-3 expressions. RESULTS: Low expressions of ITSN1 were 
      significantly associated with clinical cancer stages. RT-PCR and Western blot 
      analysis showed low expression of ITSN1 in breast cancer tissues and cell lines. 
      ITSN1 inhibition could promote cell proliferation and inhibit cell apoptosis, 
      while ITSN1 overexpression could inhibit cell proliferation and increase cell 
      apoptosis by regulating the levels of expression of Ki67 and cleaved-caspase-3. 
      CONCLUSION: The results indicated that ITSN1 could be a prognostic biomarker for 
      survivals of breast cancer patients.
CI  - (c) 2019 Xie et al.
FAU - Xie, Chen
AU  - Xie C
AD  - Department of Radiotherapy, Jiangxi Cancer Hospital, NanChang City, Jiangxi 
      Province 330029, People's Republic of China.
FAU - Xiong, Wenmin
AU  - Xiong W
AD  - Department of Radiotherapy, Jiangxi Cancer Hospital, NanChang City, Jiangxi 
      Province 330029, People's Republic of China.
FAU - Li, Junyu
AU  - Li J
AD  - Department of Radiotherapy, Jiangxi Cancer Hospital, NanChang City, Jiangxi 
      Province 330029, People's Republic of China.
FAU - Wang, Xia
AU  - Wang X
AD  - Department of Radiotherapy, Jiangxi Cancer Hospital, NanChang City, Jiangxi 
      Province 330029, People's Republic of China.
FAU - Xu, Chen
AU  - Xu C
AD  - Department of Radiotherapy, Jiangxi Cancer Hospital, NanChang City, Jiangxi 
      Province 330029, People's Republic of China.
FAU - Yang, Liping
AU  - Yang L
AD  - Department of Breast Tumor Surgery, Jiangxi Cancer Hospital, NanChang City, 
      Jiangxi Province 330029, People's Republic of China.
LA  - eng
PT  - Journal Article
DEP - 20190830
PL  - New Zealand
TA  - Onco Targets Ther
JT  - OncoTargets and therapy
JID - 101514322
PMC - PMC6722439
OTO - NOTNLM
OT  - ITSN1
OT  - apoptosis
OT  - bioinformatic analysis
OT  - breast cancer
OT  - proliferation
COIS- The authors report no conflicts of interest in this work.
EDAT- 2019/10/01 06:00
MHDA- 2019/10/01 06:01
PMCR- 2019/08/30
CRDT- 2019/10/01 06:00
PHST- 2019/05/19 00:00 [received]
PHST- 2019/08/09 00:00 [accepted]
PHST- 2019/10/01 06:00 [entrez]
PHST- 2019/10/01 06:00 [pubmed]
PHST- 2019/10/01 06:01 [medline]
PHST- 2019/08/30 00:00 [pmc-release]
AID - 216286 [pii]
AID - 10.2147/OTT.S216286 [doi]
PST - epublish
SO  - Onco Targets Ther. 2019 Aug 30;12:7079-7093. doi: 10.2147/OTT.S216286. 
      eCollection 2019.